Skip to content

Brian Anderson

UCSF Department of Psychiatry and Behavioral Sciences, UC Berkeley Center for the Science of Psychedelics, Berkeley, CA, USA.

6 papers in the library · 41 citations · publishing 2016-2026

Papers

The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry January 1, 2023 C Bree Johnston, Maria Mangini, Charles Grob et al. 33 citations

Psychedelics such as psilocybin and MDMA show promise for treating mood disorders, PTSD, prolonged grief, and psychological distress from serious illness in older adults, and may aid dementia patients or promote personal growth in healthy seniors. Both compounds act on the 5HT2A receptor and can be safely given to healthy adults under controlled conditions, but they raise blood pressure and heart rate, posing risks for older adults with cardiovascular disease. Few older adults or those with multiple health conditions have been included in clinical trials, limiting generalizability. More research is needed on safety and efficacy in this population.

A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.

Journal of psychopharmacology (Oxford, England) June 10, 2025 Torsten Passie, Anja Loizaga-Velder, Alicia Danforth et al. 4 citations

A consensus-based model curriculum for education and training in substance-assisted psychotherapy (SAP) covers theoretical topics and practical components including apprenticeship observation, ongoing clinical supervision, and self-experience for trainees. The model, developed by authors with extensive SAP experience, also addresses peer and conventional supervision, respect for intercultural differences, and teachings about indigenous use of related substances. It is largely adapted to western industrialized countries with established graduate-level psychotherapy training. The curriculum may be valuable for psychedelic researchers, those training therapists for research studies, and those preparing for clinical work outside research settings.

Santo Daime in the context of the new religious consciousness

April 8, 2016 Beatriz Caiuby Labate, Rafael Guimaraes Dos Santos, Brian Anderson et al. 2 citations

Ayahuasca, used ritually in South American religions such as Santo Daime and União do Vegetal and in Amazonian rehabilitation centers, shows therapeutic potential for treating substance dependence. Anthropological and psychiatric data indicate that ritual ayahuasca use can aid healing from addiction. The chapter reviews evidence from these settings and discusses methodological, ethical, and political considerations for future research. It places current studies in the context of psychedelic and psycholytic therapies developed between the 1950s and 1970s, emphasizing the need for interdisciplinary approaches to understand ayahuasca's role in dependence treatment.

Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.

Journal of psychopharmacology (Oxford, England) January 30, 2026 Veronica Magar, Marlena Robbins, Óscar Martín López Fernández Lobo Blanco et al. 1 citation

Indigenous Peoples have long stewarded natural psychoactive medicines through ceremony and kinship, yet their contributions are often marginalized in psychedelic science. This commentary argues for reciprocal collaboration grounded in Indigenous sovereignty, cultural rights, and governance. Drawing on traditions involving ayahuasca, psilocybin, peyote, and iboga, it illustrates how Indigenous methodologies offer critical insights for safety and efficacy. The authors call for embedding free, prior, and informed consent, equitable benefit-sharing, and Indigenous leadership in research and policy, moving beyond tokenism toward systemic change. They conclude by urging formal, transparent convening processes modeled on WHO global consultations to bring Indigenous leaders, researchers, and policymakers together.

Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients

Journal of Health Service Psychology December 1, 2025 Philip Garrity, Alicia Danforth, Brian Anderson et al. 1 citation

Psilocybin shows promise in enhancing well-being for patients with terminal illnesses. In a clinical trial involving 50 participants, 80% reported significant improvements in existential distress and quality of life after receiving psilocybin therapy. This innovative approach combines traditional medicine with psychosocial support, suggesting that psychedelics can bridge gaps in palliative care. Participants also experienced altered interpretations of their pain and meaning in life, highlighting the potential of integrating psychedelics into psychological practice to address deep-seated beliefs and existential concerns.

Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men

Palliative Medicine Reports January 1, 2026 Hannah Whitmore, Maria Mangini, Heather Leutwyler et al.

Group psilocybin-assisted therapy may help older long-term AIDS survivor gay men accept death, dying, and impermanence, as well as their illness and complex emotions. This secondary qualitative analysis of interviews from six participants found three major themes: acceptance of death, acceptance of illness, and embracing complex emotions. The findings suggest that the therapy fosters death acceptance by helping participants accept their illness and engage with the full range of emotions that arise when facing mortality. Further studies are needed to validate these results, which highlight the importance of focusing on death acceptance in psychedelic research with seriously ill populations.